A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-06

AUTHORS

Evan M. Hersh, Steven J. O’Day, John Powderly, Khuda D. Khan, Anna C. Pavlick, Lee D. Cranmer, Wolfram E. Samlowski, Geoffrey M. Nichol, Michael J. Yellin, Jeffrey S. Weber

ABSTRACT

OBJECTIVE: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. METHODS: Chemotherapy-naïve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m(2)/day. The primary efficacy endpoint was objective response rate. RESULTS: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n = 35; ipilimumab, n = 37). The objective response rate was 14.3% (95% CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4% (95% CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n = 32) and ipilimumab alone (n = 32), respectively, median overall survival was 14.3 months (95% CI, 10.2-18.8) and 11.4 months (95% CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62%, 24% and 20% for the ipilimumab plus DTIC group and were 45%, 21% and 9% for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7% of patients in the combination group versus 53.8% in the monotherapy group, with 17.1% and 7.7% ≥grade 3, respectively. CONCLUSION: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC. More... »

PAGES

489-498

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-009-9376-8

DOI

http://dx.doi.org/10.1007/s10637-009-9376-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021055401

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20082117


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dacarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Demography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipilimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Subsets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hersh", 
        "givenName": "Evan M.", 
        "id": "sg:person.016076461657.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016076461657.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Angeles Clinic and Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.488730.0", 
          "name": [
            "The Angeles Clinic and Research Institute, 2001 Santa Monica Blvd, Suite 560W, 90404, Santa Monica, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Day", 
        "givenName": "Steven J.", 
        "id": "sg:person.0613540622.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613540622.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Carolina BioOncology Institute", 
          "id": "https://www.grid.ac/institutes/grid.488747.0", 
          "name": [
            "Carolina Bio-Oncology Institute, Cancer Therapy & Research Center, 9801 W. Kincey Ave, Suite 145, 28078, Huntersville, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powderly", 
        "givenName": "John", 
        "id": "sg:person.01072502357.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072502357.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Franciscan Health Indianapolis", 
          "id": "https://www.grid.ac/institutes/grid.492675.b", 
          "name": [
            "St. Francis Hospital & Health Centers, 8111 S. Emerson Ave, 46237, Indianapolis, IN, USA", 
            "Elizabethtown Hematology & Oncology, 1107 Woodland Drive, 42701, Elizabethtown, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Khuda D.", 
        "id": "sg:person.01157414103.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157414103.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University Langone Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.240324.3", 
          "name": [
            "New York University Medical Center, 160 East 34th Street, 10016, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavlick", 
        "givenName": "Anna C.", 
        "id": "sg:person.01276612250.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276612250.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cranmer", 
        "givenName": "Lee D.", 
        "id": "sg:person.01106334210.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106334210.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UC San Diego Health System", 
          "id": "https://www.grid.ac/institutes/grid.420234.3", 
          "name": [
            "Nevada Cancer Institute, One Breakthrough Way, 89135, Las Vegas, NV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samlowski", 
        "givenName": "Wolfram E.", 
        "id": "sg:person.01166371124.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166371124.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Medarex, Inc, 707 State Road, 08540, Princeton, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nichol", 
        "givenName": "Geoffrey M.", 
        "id": "sg:person.010723245237.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010723245237.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Medarex, Inc, 707 State Road, 08540, Princeton, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yellin", 
        "givenName": "Michael J.", 
        "id": "sg:person.01020215452.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020215452.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Moffitt Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.468198.a", 
          "name": [
            "H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weber", 
        "givenName": "Jeffrey S.", 
        "id": "sg:person.012212763107.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012212763107.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1080/07357900701522315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003059085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015813726", 
          "https://doi.org/10.1038/nrc2051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.12-7-864", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016305749"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-1024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016716683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.0483", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017094741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.1927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019613948"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2007.08.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020790340"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/aso.2005.03.536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024972195", 
          "https://doi.org/10.1245/aso.2005.03.536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/aso.2005.03.536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024972195", 
          "https://doi.org/10.1245/aso.2005.03.536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-1624", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028571226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/era.09.25", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030498193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.17.8954", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034543033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037454639", 
          "https://doi.org/10.1038/nrc1613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037454639", 
          "https://doi.org/10.1038/nrc1613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2133.2004.05708.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037745378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00128071-200809050-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039147548", 
          "https://doi.org/10.2165/00128071-200809050-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039486303"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.1533209100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042168438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-008-0653-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043129240", 
          "https://doi.org/10.1007/s00262-008-0653-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-008-0653-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043129240", 
          "https://doi.org/10.1007/s00262-008-0653-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/edm.09.11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044359610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0830997100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045843488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2007.04.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045975073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.7837", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046075678"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70334-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053423975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1548-5315(11)70470-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054717937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712598.7.8.1245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067589940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077165836", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.3018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079371269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.9021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079374508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.9063", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079374683"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-06", 
    "datePublishedReg": "2011-06-01", 
    "description": "OBJECTIVE: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma.\nMETHODS: Chemotherapy-na\u00efve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m(2)/day. The primary efficacy endpoint was objective response rate.\nRESULTS: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n\u2009=\u200935; ipilimumab, n\u2009=\u200937). The objective response rate was 14.3% (95% CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4% (95% CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n\u2009=\u200932) and ipilimumab alone (n\u2009=\u200932), respectively, median overall survival was 14.3 months (95% CI, 10.2-18.8) and 11.4 months (95% CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62%, 24% and 20% for the ipilimumab plus DTIC group and were 45%, 21% and 9% for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7% of patients in the combination group versus 53.8% in the monotherapy group, with 17.1% and 7.7% \u2265grade 3, respectively.\nCONCLUSION: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-009-9376-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "name": "A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma", 
    "pagination": "489-498", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6451dc89034eff9369abb686e0aff6ffb2300acea4baaaf4043f68069a414157"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20082117"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-009-9376-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021055401"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-009-9376-8", 
      "https://app.dimensions.ai/details/publication/pub.1021055401"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000512.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-009-9376-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-009-9376-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-009-9376-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-009-9376-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-009-9376-8'


 

This table displays all metadata directly associated to this object as RDF triples.

320 TRIPLES      21 PREDICATES      77 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-009-9376-8 schema:about N1f4e58b56b1f4d50b8b33f9b60b52602
2 N2fcf9beb96124e63a77bdc9dae133da0
3 N380ed1eccd1748e7af4d19ef1a7f1033
4 N460acee6e2d14cada7992452a0f7c9aa
5 N61f9eece9beb49488b849d08255e4993
6 N6c39a5745a474f39afe824a94fb43dca
7 N718965df88c54fa4bf06d15b12e79cbd
8 N742e67ac1d244618b4034e4f1d5e1dd5
9 N78006a6f35024096aacf7889b2bec72e
10 N7bd62c3de28c4b4aa784bbde771d1e86
11 N92c3f8f33c1e42a69508dc8fe6bc2796
12 N9dcddfdb379a4baf93cf1dc1773bc608
13 Nae368a9e907b4caeb731800b1602ef4f
14 Nb9aacdd6119f498699585113d3f4de16
15 Ndb1626ebb17e47c3a16d6b5511338803
16 Neb9d4c56a2cb48369c4da6cf4882c6ba
17 Nee03df4e81ae46b494951c848deb35c0
18 Nf350b0c06ff54d519f418a732af32e38
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nd8c79066c31148bca36d4e5e746850c4
22 schema:citation sg:pub.10.1007/s00262-008-0653-8
23 sg:pub.10.1038/nrc1613
24 sg:pub.10.1038/nrc2051
25 sg:pub.10.1245/aso.2005.03.536
26 sg:pub.10.2165/00128071-200809050-00004
27 https://app.dimensions.ai/details/publication/pub.1077165836
28 https://doi.org/10.1016/j.ccr.2007.08.023
29 https://doi.org/10.1016/j.ctrv.2007.04.003
30 https://doi.org/10.1016/s1470-2045(09)70334-1
31 https://doi.org/10.1016/s1548-5315(11)70470-3
32 https://doi.org/10.1073/pnas.0830997100
33 https://doi.org/10.1073/pnas.1533209100
34 https://doi.org/10.1080/07357900701522315
35 https://doi.org/10.1093/jnci/92.3.205
36 https://doi.org/10.1111/j.1365-2133.2004.05708.x
37 https://doi.org/10.1158/1078-0432.ccr-09-1024
38 https://doi.org/10.1158/1078-0432.ccr-09-1624
39 https://doi.org/10.1200/jco.2005.01.109
40 https://doi.org/10.1200/jco.2005.06.205
41 https://doi.org/10.1200/jco.2006.06.0483
42 https://doi.org/10.1200/jco.2007.12.7837
43 https://doi.org/10.1200/jco.2008.16.1927
44 https://doi.org/10.1200/jco.2008.17.8954
45 https://doi.org/10.1200/jco.2008.26.15_suppl.3018
46 https://doi.org/10.1200/jco.2008.26.15_suppl.9021
47 https://doi.org/10.1200/jco.2008.26.15_suppl.9063
48 https://doi.org/10.1517/14712598.7.8.1245
49 https://doi.org/10.1586/edm.09.11
50 https://doi.org/10.1586/era.09.25
51 https://doi.org/10.1634/theoncologist.12-7-864
52 schema:datePublished 2011-06
53 schema:datePublishedReg 2011-06-01
54 schema:description OBJECTIVE: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. METHODS: Chemotherapy-naïve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m(2)/day. The primary efficacy endpoint was objective response rate. RESULTS: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n = 35; ipilimumab, n = 37). The objective response rate was 14.3% (95% CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4% (95% CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n = 32) and ipilimumab alone (n = 32), respectively, median overall survival was 14.3 months (95% CI, 10.2-18.8) and 11.4 months (95% CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62%, 24% and 20% for the ipilimumab plus DTIC group and were 45%, 21% and 9% for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7% of patients in the combination group versus 53.8% in the monotherapy group, with 17.1% and 7.7% ≥grade 3, respectively. CONCLUSION: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC.
55 schema:genre research_article
56 schema:inLanguage en
57 schema:isAccessibleForFree false
58 schema:isPartOf N2dba7f8739aa436ca602751487c03d44
59 Nc794eee3c1324963a62b26d2987e7379
60 sg:journal.1094201
61 schema:name A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
62 schema:pagination 489-498
63 schema:productId N34b7d1f777ee408dbeda344aa7d5ddf9
64 N56e8082e5d24475f9486799572290d13
65 Nb05a698ed7f44d44aca9114ace28b4f0
66 Nb2c0ec7403a749868217dee5c855b82a
67 Ncfbcc15ea5ed4b6ebe55515dfda8f958
68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021055401
69 https://doi.org/10.1007/s10637-009-9376-8
70 schema:sdDatePublished 2019-04-10T22:31
71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
72 schema:sdPublisher N1c61edaa6c6f40b69fc87bf2adbb8abe
73 schema:url http://link.springer.com/10.1007%2Fs10637-009-9376-8
74 sgo:license sg:explorer/license/
75 sgo:sdDataset articles
76 rdf:type schema:ScholarlyArticle
77 N04ad9d178e104822a59dba0535ae2962 rdf:first sg:person.0613540622.72
78 rdf:rest Na756fcb9cace4c72b8380a6b9ab9559b
79 N1c61edaa6c6f40b69fc87bf2adbb8abe schema:name Springer Nature - SN SciGraph project
80 rdf:type schema:Organization
81 N1f4e58b56b1f4d50b8b33f9b60b52602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Demography
83 rdf:type schema:DefinedTerm
84 N1f6d78b434d848678c7088aba5308c7d rdf:first sg:person.01166371124.26
85 rdf:rest N2ad7d0a3a1c442b1b8bc339a13ea0457
86 N2ad7d0a3a1c442b1b8bc339a13ea0457 rdf:first sg:person.010723245237.64
87 rdf:rest N744a9527631c430ca7d597516324924c
88 N2dba7f8739aa436ca602751487c03d44 schema:issueNumber 3
89 rdf:type schema:PublicationIssue
90 N2fcf9beb96124e63a77bdc9dae133da0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Antineoplastic Agents
92 rdf:type schema:DefinedTerm
93 N34b7d1f777ee408dbeda344aa7d5ddf9 schema:name readcube_id
94 schema:value 6451dc89034eff9369abb686e0aff6ffb2300acea4baaaf4043f68069a414157
95 rdf:type schema:PropertyValue
96 N380ed1eccd1748e7af4d19ef1a7f1033 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Melanoma
98 rdf:type schema:DefinedTerm
99 N449bb9c112b048dab46102eba41cdb2f rdf:first sg:person.01106334210.93
100 rdf:rest N1f6d78b434d848678c7088aba5308c7d
101 N460acee6e2d14cada7992452a0f7c9aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antineoplastic Combined Chemotherapy Protocols
103 rdf:type schema:DefinedTerm
104 N56e8082e5d24475f9486799572290d13 schema:name pubmed_id
105 schema:value 20082117
106 rdf:type schema:PropertyValue
107 N61f9eece9beb49488b849d08255e4993 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Female
109 rdf:type schema:DefinedTerm
110 N6c39a5745a474f39afe824a94fb43dca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Aged, 80 and over
112 rdf:type schema:DefinedTerm
113 N718965df88c54fa4bf06d15b12e79cbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Kaplan-Meier Estimate
115 rdf:type schema:DefinedTerm
116 N742e67ac1d244618b4034e4f1d5e1dd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Neoplasm Staging
118 rdf:type schema:DefinedTerm
119 N744a9527631c430ca7d597516324924c rdf:first sg:person.01020215452.48
120 rdf:rest N79003d3c8a49470c941c2f87debcad45
121 N78006a6f35024096aacf7889b2bec72e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Aged
123 rdf:type schema:DefinedTerm
124 N79003d3c8a49470c941c2f87debcad45 rdf:first sg:person.012212763107.60
125 rdf:rest rdf:nil
126 N7bd62c3de28c4b4aa784bbde771d1e86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Male
128 rdf:type schema:DefinedTerm
129 N883fbd9930df43e0bfc1f873aef97202 rdf:first sg:person.01157414103.44
130 rdf:rest Naa2a98ddfcc24f35ac268329ee52adb9
131 N92c3f8f33c1e42a69508dc8fe6bc2796 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Humans
133 rdf:type schema:DefinedTerm
134 N9dcddfdb379a4baf93cf1dc1773bc608 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Dacarbazine
136 rdf:type schema:DefinedTerm
137 Na756fcb9cace4c72b8380a6b9ab9559b rdf:first sg:person.01072502357.79
138 rdf:rest N883fbd9930df43e0bfc1f873aef97202
139 Naa2a98ddfcc24f35ac268329ee52adb9 rdf:first sg:person.01276612250.59
140 rdf:rest N449bb9c112b048dab46102eba41cdb2f
141 Nae368a9e907b4caeb731800b1602ef4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Adult
143 rdf:type schema:DefinedTerm
144 Nb05a698ed7f44d44aca9114ace28b4f0 schema:name dimensions_id
145 schema:value pub.1021055401
146 rdf:type schema:PropertyValue
147 Nb2c0ec7403a749868217dee5c855b82a schema:name nlm_unique_id
148 schema:value 8309330
149 rdf:type schema:PropertyValue
150 Nb9aacdd6119f498699585113d3f4de16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Lymphocyte Subsets
152 rdf:type schema:DefinedTerm
153 Nc794eee3c1324963a62b26d2987e7379 schema:volumeNumber 29
154 rdf:type schema:PublicationVolume
155 Ncfbcc15ea5ed4b6ebe55515dfda8f958 schema:name doi
156 schema:value 10.1007/s10637-009-9376-8
157 rdf:type schema:PropertyValue
158 Nd8c79066c31148bca36d4e5e746850c4 rdf:first sg:person.016076461657.32
159 rdf:rest N04ad9d178e104822a59dba0535ae2962
160 Ndb1626ebb17e47c3a16d6b5511338803 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Middle Aged
162 rdf:type schema:DefinedTerm
163 Neb9d4c56a2cb48369c4da6cf4882c6ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Antibodies, Monoclonal
165 rdf:type schema:DefinedTerm
166 Nee03df4e81ae46b494951c848deb35c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Ipilimumab
168 rdf:type schema:DefinedTerm
169 Nf350b0c06ff54d519f418a732af32e38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Treatment Outcome
171 rdf:type schema:DefinedTerm
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
176 schema:name Oncology and Carcinogenesis
177 rdf:type schema:DefinedTerm
178 sg:journal.1094201 schema:issn 0167-6997
179 1573-0646
180 schema:name Investigational New Drugs
181 rdf:type schema:Periodical
182 sg:person.01020215452.48 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
183 schema:familyName Yellin
184 schema:givenName Michael J.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020215452.48
186 rdf:type schema:Person
187 sg:person.010723245237.64 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
188 schema:familyName Nichol
189 schema:givenName Geoffrey M.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010723245237.64
191 rdf:type schema:Person
192 sg:person.01072502357.79 schema:affiliation https://www.grid.ac/institutes/grid.488747.0
193 schema:familyName Powderly
194 schema:givenName John
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072502357.79
196 rdf:type schema:Person
197 sg:person.01106334210.93 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
198 schema:familyName Cranmer
199 schema:givenName Lee D.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106334210.93
201 rdf:type schema:Person
202 sg:person.01157414103.44 schema:affiliation https://www.grid.ac/institutes/grid.492675.b
203 schema:familyName Khan
204 schema:givenName Khuda D.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157414103.44
206 rdf:type schema:Person
207 sg:person.01166371124.26 schema:affiliation https://www.grid.ac/institutes/grid.420234.3
208 schema:familyName Samlowski
209 schema:givenName Wolfram E.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166371124.26
211 rdf:type schema:Person
212 sg:person.012212763107.60 schema:affiliation https://www.grid.ac/institutes/grid.468198.a
213 schema:familyName Weber
214 schema:givenName Jeffrey S.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012212763107.60
216 rdf:type schema:Person
217 sg:person.01276612250.59 schema:affiliation https://www.grid.ac/institutes/grid.240324.3
218 schema:familyName Pavlick
219 schema:givenName Anna C.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276612250.59
221 rdf:type schema:Person
222 sg:person.016076461657.32 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
223 schema:familyName Hersh
224 schema:givenName Evan M.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016076461657.32
226 rdf:type schema:Person
227 sg:person.0613540622.72 schema:affiliation https://www.grid.ac/institutes/grid.488730.0
228 schema:familyName O’Day
229 schema:givenName Steven J.
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613540622.72
231 rdf:type schema:Person
232 sg:pub.10.1007/s00262-008-0653-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043129240
233 https://doi.org/10.1007/s00262-008-0653-8
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/nrc1613 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037454639
236 https://doi.org/10.1038/nrc1613
237 rdf:type schema:CreativeWork
238 sg:pub.10.1038/nrc2051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015813726
239 https://doi.org/10.1038/nrc2051
240 rdf:type schema:CreativeWork
241 sg:pub.10.1245/aso.2005.03.536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024972195
242 https://doi.org/10.1245/aso.2005.03.536
243 rdf:type schema:CreativeWork
244 sg:pub.10.2165/00128071-200809050-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039147548
245 https://doi.org/10.2165/00128071-200809050-00004
246 rdf:type schema:CreativeWork
247 https://app.dimensions.ai/details/publication/pub.1077165836 schema:CreativeWork
248 https://doi.org/10.1016/j.ccr.2007.08.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020790340
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/j.ctrv.2007.04.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045975073
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1016/s1470-2045(09)70334-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053423975
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/s1548-5315(11)70470-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054717937
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1073/pnas.0830997100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045843488
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1073/pnas.1533209100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042168438
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1080/07357900701522315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003059085
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1111/j.1365-2133.2004.05708.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037745378
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1158/1078-0432.ccr-09-1024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016716683
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1158/1078-0432.ccr-09-1624 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028571226
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.2005.01.109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039486303
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1200/jco.2005.06.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021025524
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1200/jco.2006.06.0483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017094741
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1200/jco.2007.12.7837 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046075678
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1200/jco.2008.16.1927 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019613948
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1200/jco.2008.17.8954 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034543033
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1200/jco.2008.26.15_suppl.3018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079371269
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1200/jco.2008.26.15_suppl.9021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079374508
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1200/jco.2008.26.15_suppl.9063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079374683
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1517/14712598.7.8.1245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067589940
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1586/edm.09.11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044359610
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1586/era.09.25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030498193
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1634/theoncologist.12-7-864 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016305749
295 rdf:type schema:CreativeWork
296 https://www.grid.ac/institutes/grid.134563.6 schema:alternateName University of Arizona
297 schema:name Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, 85724, Tucson, AZ, USA
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.240324.3 schema:alternateName New York University Langone Medical Center
300 schema:name New York University Medical Center, 160 East 34th Street, 10016, New York, NY, USA
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.419971.3 schema:alternateName Bristol-Myers Squibb (United States)
303 schema:name Medarex, Inc, 707 State Road, 08540, Princeton, NJ, USA
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.420234.3 schema:alternateName UC San Diego Health System
306 schema:name Nevada Cancer Institute, One Breakthrough Way, 89135, Las Vegas, NV, USA
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.468198.a schema:alternateName Moffitt Cancer Center
309 schema:name H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.488730.0 schema:alternateName Angeles Clinic and Research Institute
312 schema:name The Angeles Clinic and Research Institute, 2001 Santa Monica Blvd, Suite 560W, 90404, Santa Monica, CA, USA
313 rdf:type schema:Organization
314 https://www.grid.ac/institutes/grid.488747.0 schema:alternateName Carolina BioOncology Institute
315 schema:name Carolina Bio-Oncology Institute, Cancer Therapy & Research Center, 9801 W. Kincey Ave, Suite 145, 28078, Huntersville, NC, USA
316 rdf:type schema:Organization
317 https://www.grid.ac/institutes/grid.492675.b schema:alternateName Franciscan Health Indianapolis
318 schema:name Elizabethtown Hematology & Oncology, 1107 Woodland Drive, 42701, Elizabethtown, KY, USA
319 St. Francis Hospital & Health Centers, 8111 S. Emerson Ave, 46237, Indianapolis, IN, USA
320 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...